Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Tobira Therapeutics is recruiting for a Phase IIb study of its CCR5/CCR2 entry inhibitor cenicriviroc (TBR-652). It is hoped that cenicriviroc...
TBR-652 not only has promising activity against HIV but may also have important disease-reducing anti-inflammatory properties
TBR-652, a CCR5 receptor antagonist being developed by Tobira Therapeutics, was safe and well tolerated in a small 10-day study reported on We...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.